Common and emerging fungal pulmonary infections

Infectious Disease Clinics of North America

Volumn 24, Issue 3, 2010, Pages 557-577

  Hsu, Li Yang ^a   Ng, Esther Shu Ting ^a   Koh, Liang Piu ^a  

^a NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

Author keywords

Antifungal agents; Antifungal drug resistance; Diagnostic tests; Epidemiology; Prevention and control; Pulmonary fungal infections

Indexed keywords

AMPHOTERICIN B; COTRIMOXAZOLE; DEFERASIROX; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; METHYLPREDNISOLONE; POSACONAZOLE; SULFONAMIDE; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE; ANTIFUNGAL AGENT; IMMUNOLOGIC FACTOR;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLUS; BLASTOMYCES DERMATITIDIS; BLASTOMYCOSIS; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; CRYPTOCOCCUS GATTII; GRAFT RECIPIENT; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; HYALOHYPHOMYCOSIS; IMMUNOCOMPROMISED PATIENT; LUNG MYCOSIS; MOULD; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PARACOCCIDIOIDES BRASILIENSIS; PENICILLIOSIS; PENICILLIUM MARNEFFEI; PREVALENCE; PULMONARY CRYPTOCOCCOSIS; REVIEW; SOUTH AMERICAN BLASTOMYCOSIS; SPOROTRICHOSIS; VULNERABLE POPULATION; ZYGOMYCETES; ZYGOMYCOSIS; ANTIFUNGAL RESISTANCE; CHEMOPROPHYLAXIS; COMPLICATION; DRUG EFFECTS; FUNGUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; LUNG DISEASES, FUNGAL; MICROBIOLOGY; PROCEDURES;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; DRUG RESISTANCE, FUNGAL; FUNGI; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC FACTORS; LUNG DISEASES, FUNGAL;

EID: 77955238359     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.04.003     Document Type: Review

References (95)

1. Lass-Flörl C. The changing face of epidemiology of invasive fungal disease in Europe. Mycoses 2009, 52(3):197-205.
2. Erjavec Z., Kluin-Nelemans H., Verweij P.E. Trends in invasive fungal infections, with emphasis on invasive aspergillosis. Clin Microbiol Infect 2009, 15(7):625-633.
3. Malani A.N., Kauffman C.A. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007, 67:1803-1812.
4. Richardson M., Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect 2008, 14(Suppl 4):5-24.
5. Marr K.A. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol 2010, 22(2):138-142.
6. Lewis R.E. Overview of the changing epidemiology of candidemia. Curr Med Res Opin 2009, 25(7):1732-1740.
7. Mann P.A., McNicholas P.M., Chau A.S., et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother 2009, 53(12):5026-5034.
8. Pongas G.N., Lewis R.E., Samonis G., et al. Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?. Clin Microbiol Infect 2009, 15(Suppl 5):93-97.
9. Greer A., Ng V., Fisman D. Climate change and infectious diseases in North America: the road ahead. CMAJ 2008, 178(6):715-722.
10. Datta K., Bartlett K.H., Marr K.A. Cryptococcus gattii: emergence in western North America: exploitation of a novel ecological niche. Interdiscip Perspect Infect Dis 2009, 2009:176532.
11. Kauffman C.A. Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis. Infect Dis Clin North Am 2006, 20(3):645-662. vii.
12. Wickes B.L., Mayorga M.E., Edman U., et al. Dimorphism and haploid fruiting in Cryptococcus neoformans: association with the α-mating type. Proc Natl Acad Sci U S A 1996, 93(14):7327-7331.
13. Loulergue P., Bastides F., Baudouin V., et al. Literature review and case histories of Histoplasma capsulatum var. duboisii infections in HIV-infected patients. Emerg Infect Dis 2007, 13(11):1647-1652.
14. Wheat L.J., Freifeld A.G., Kleiman M.B., et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45(7):807-825.
15. Cuellar-Rodriguez J., Avery R.K., Lard M., et al. Histoplasmosis in solid organ transplant recipients: 10 years of experience at a large transplant center in an endemic area. Clin Infect Dis 2009, 49(5):710-716.
16. Wheat L.J., Conces D., Allen S.D., et al. Pulmonary histoplasmosis syndromes: recognition, diagnosis and management. Semin Respir Crit Care Med 2004, 25(2):129-144.
17. Gurney J.W., Conces D.J. Pulmonary histoplasmosis. Radiology 1996, 199(2):297-306.
18. Sathapatayavongs B., Batteiger B.E., Wheat J., et al. Clinical and laboratory features of disseminated histoplasmosis during two large urban outbreaks. Medicine (Baltimore) 1983, 62(5):263-270.
19. Wheat L.J. Approach to the diagnosis of endemic mycoses. Clin Chest Med 2009, 30(2):379-389. viii.
20. Hage C.A., Davis T.E., Fuller D., et al. Diagnosis of histoplasmosis by antigen detection in bronchoalveolar fluid. Chest 2010, 137(3):623-628.
21. Lenhart S.W., Schafer M.P., Singal M., et al. NIOSH: histoplasmosis:. protecting workers at risk - revised edition. 2004, Available at:, Accessed May 22, 2010. http://www.elcosh.org/en/document/718/d000679/niosh%253A-histoplasmosis%253A-protecting-workers-at-risk-revised-edition.html.
22. Laniado-Laborin R. Expanding understanding of epidemiology of coccidioidomycosis in the Western hemisphere. Ann N Y Acad Sci 2007, 1111:19-34.
23. Centers for Disease Control and Prevention (CDC) Increase in coccidioidomycosis-California, 2000-2007. MMWR Morb Mortal Wkly Rep 2009, 58(5):105-109.
24. Smith C.E., Beard R.R., Whiting E.G., et al. Varieties of coccidioidal infection in relation to the epidemiology and control of the disease. Am J Public Health 1946, 36:1394-1402.
25. Kirkland T.N., Fierer J. Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis 1996, 2(3):192-199.
26. Galgiani J. Coccidioides immitis. Principles and practice of infectious diseases 2000, 2746-2757. Churchill Livingstone, Philadelphia. 5th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
27. Sutton D.A. Diagnosis of coccidioidomycosis by culture: safety considerations, traditional methods, and susceptibility testing. Ann N Y Acad Sci 2007, 1111:315-325.
28. Galgiani J.N., Ampel N.M., Blair J.E., et al. Coccidioidomycosis. Clin Infect Dis 2005, 41(9):1217-1223.
29. Woods C.W., McRill C., Plikaytis B.D., et al. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med 1993, 94(3):235-240.
30. Blair J.E. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides spp. Curr Opin Infect Dis 2008, 21(4):415-420.
31. Chapman S.W., Dismukes W.E., Proia L.A., et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008, 46(12):1801-1812.
32. Chang W.L., Audet R.G., Aizenstein B.D., et al. T-cell epitopes and human leukocyte antigen restriction elements of an immunodominant antigen of Blastomyces dermatitidis. Infect Immun 2000, 68(2):502-510.
33. Brown L.R., Sweasen S.J., VanScoy R.E., et al. Roentgenologic features of pulmonary blastomycosis. Mayo Clin Proc 1991, 66:29-38.
34. Pappas P.G., Threlkeld M.G., Bedsole G.D., et al. Blastomycosis in immunocompromised patients. Medicine (Baltimore) 1993, 72(5):311-325.
35. Gauthier G.M., Safdar N., Klein B.S., et al. Blastomycosis in solid organ transplant recipients. Transpl Infect Dis 2007, 9:310-317.
36. Pappas P.G., Pottage J.C., Powderly W.G., et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992, 116:847-853.
37. Restrepo A., Benard G., de Castro C.C., et al. Pulmonary paracoccidioidomycosis. Semin Respir Crit Care Med 2008, 29(2):182-197.
38. Laniado-Laborin R. Coccidioidomycosis and other endemic mycoses in Mexico. Rev Iberoam Micol 2007, 24(4):249-258.
39. Theodoro R.C., Bagagli E., Oliveira C. Phylogenetic analysis of PRP8 intein in Paracoccidioides brasiliensis species complex. Fungal Genet Biol 2008, 45(9):1284-1291.
40. Morejón K.M., Machado A.A., Martinez R. Paracoccidioidomycosis in patients infected with and not infected with human immunodeficiency virus: a case-control study. Am J Trop Med Hyg 2009, 80(3):359-366.
41. de Camargo Z.P. Serology of paracoccidioidomycosis. Mycopathologia 2008, 165(4-5):289-302.
42. Marques da Silva S.H., Colombo A.L., Blotta M.H., et al. Detection of circulating gp43 antigen in serum, cerebrospinal fluid, and bronchoalveolar lavage fluid of patients with paracoccidioidomycosis. J Clin Microbiol 2003, 41(8):3675-3680.
43. Shikanai-Yasuda M.A., Telles Filho Fde Q., Mendes R.P., et al. Rev Soc Bras Med Trop 2006, 39(3):297-310. [in Portuguese].
44. Vanittanakom N., Cooper C.R., Fisher M.C., et al. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev 2006, 19(1):95-110. [Review].
45. Supparatpinyo K., Khamwan C., Baosoung V., et al. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994, 344(8915):110-113.
46. Capponi M., Sureau P., Segretain G. Bull Soc Pathol Exot 1956, 49(3):418-421. [in French].
47. Fisher M., Aanensen C.D., de Hoog S., et al. Multilocus microsatellite typing system for Penicillium marneffei reveals spatially structured populations. J Clin Microbiol 2004, 42(11):5065-5069.
48. Duong T.A. Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases. Clin Infect Dis 1996, 23(1):125-130.
49. Huang Y.T., Hung C.C., Liao C.H., et al. Detection of circulating galactomannan in serum samples for diagnosis of Penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. J Clin Microbiol 2007, 45(9):2858-2862.
50. Supparatpinyo K., Nelson K.E., Merz W.G., et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother 1993, 37(11):2407-2411.
51. Sirisanthana T., Supparatpinyo K., Perriens J., et al. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infections and human immunodeficiency virus-infected patients. Clin Infect Dis 1998, 26(5):1107-1110.
52. Chalwarith R., Charoenyos N., Sirisanthana T., et al. Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART. AIDS 2007, 21(3):365-367.
53. Kauffman C.A., Bustamante B., Chapman S.W., et al. Clinical practice guidelines for the management of sporotrichosis: 2007 updated by the Infectious Diseases Society of America. Clin Infect Dis 2007, 45(10):1255-1265.
54. Pluss J.L., Opal S.M. Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore) 1986, 65(3):143-153.
55. Bernardes-Engemann A.R., Costa R.C., Miguens B.R., et al. Development of an enzyme-linked immunosorbent assay for the serodiagnosis of several clinical forms of sporotrichosis. Med Mycol 2005, 43(6):487-493.
56. Tomblyn M., Chiller T., Einsele H., et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15(10):1143-1238.
57. Sugar A.M. Agents of mucormycosis and related species. Principles and practice of infectious diseases 2000, 2685-2695. Churchill Livingstone, Philadelphia. 5th edition. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
58. Chayakulkeeree M., Ghannoum M.A., Perfect J.R. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006, 25(4):215-229.
59. Gupta K.L., Khullar D.K., Behera D., et al. Pulmonary mucormycosis presenting as fatal massive haemoptysis in a renal transplant recipient. Nephrol Dial Transplant 1998, 13(12):3258-3260.
60. Rubin S.A., Chaljub G., Winer-Muram H.T., et al. Pulmonary zygomycosis: a radiographic and clinical spectrum. J Thorac Imaging 1992, 7(4):85-90.
61. Chamilos G., Marom E.M., Lewis R.E., et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 2005, 41(1):60-66.
62. Hachem R.Y., Kontoyiannis D.P., Chemaly R.F., et al. Utility of galactomannan enzyme immunoassay and (1,3) beta-D-glucan in diagnosis of invasive fungal infections: low sensitivity for Aspergillus fumigatus infection in hematologic malignancy patients. J Clin Microbiol 2009, 47(1):129-133.
63. Perfect J.R. Use of newer antifungal therapies in clinical practice: what do the data tell us?. Oncology (Williston Park) 2004, 18(13 Suppl 7):15-23.
64. Van Burik J.H., Hare R.S., Solomon H.F., et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 2006, 42:e61-e65.
65. Spellberg B., Andes D., Perez M., et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009, 53(7):3122-3125.
66. Gil-Lamaignere C., Simitsopoulou M., Roilides E., et al. Interferon-gamma and granulocyte macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 2005, 191(7):1180-1187.
67. Lekakis L.J., Lawson A., Prante J., et al. Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature. Biol Blood Marrow Transplant 2009, 15(8):991-995.
68. Naggie S., Perfect J.R. Molds: hyalohyphomycosis, phaeohyphomycosis and zygomycosis. Clin Chest Med 2009, 30(2):337-353. vii-viii.
69. Saw S.M., Ooi P.L., Tan D.T., et al. Risk factors for contact lens-related fusarium keratitis: a case-control study in Singapore. Arch Ophthalmol 2007, 125(5):611-617.
70. Nucci M., Marr K.A., Queiroz-Telles F., et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004, 38(9):1237-1242.
71. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997, 90(3):999-1008.
72. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007, 20(4):697-704.
73. Cimon B., Carrère J., Vinatier J.F., et al. Clinical significance of Scedosporium apiospermum in patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2000, 19(1):53-56.
74. Katragkou A., Dotis J., Kotsiou M., et al. Scedosporium apiospermum infection after near-drowning. Mycoses 2007, 50(5):412-421.
75. Jacobson E.S. Pathogenic roles for fungal melanins. Clin Microbiol Rev 2000, 13(4):708-717.
76. Lake F.R., Froudist J.H., McAleer R., et al. Allergic bronchopulmonary fungal disease caused by Bipolaris and Curvularia. Aust N Z J Med 1991, 21(6):871-874.
77. Malde B., Greenberger P.A. Allergic bronchopulmonary aspergillosis. Allergy Asthma Proc 2004, 25(4 Suppl 1):S38-S39.
78. Revankar S.G. Phaeohyphomycosis. Infect Dis Clin North Am 2006, 20(3):609-620.
79. Gugnani H.C., Mitchell T.G., Litvintseva A.P., et al. Isolation of Cryptococcus gattii and Cryptococcus neoformans var grubii from the flowers and bark of Eucalyptus trees in India. Med Mycol 2005, 43(6):565-569.
80. Hoang L.M., Maguire J.A., Doyle P., et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology. J Med Microbiol 2004, 53(Pt 9):935-940.
81. Pappas P.G., Perfect J.R., Cloud G.A., et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001, 33(5):690-699.
82. Zinck S.E., Leung A.N., Frost M., et al. Pulmonary cryptococcosis: CT and pathologic findings. J Comput Assist Tomogr 2002, 26(3):330-334.
83. Vilchez R.A., Linden P., Lacomis J., et al. Acute respiratory failure associated with pulmonary cryptococcosis in non-AIDS patients. Chest 2001, 119(6):1865-1869.
84. Saag M.S., Graybill R.J., Larsen R.A., et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000, 30(4):710-718.
85. Nadrous H.F., Antonios V.S., Terrell C.L., et al. Pulmonary cryptococcosis in nonimmunocompromised patients. Chest 2003, 124(6):2143-2147.
86. Lee J.H., Slifman N.R., Gershon S.K., et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and ethanercept. Arthritis Rheum 2002, 46(10):2565-2570.
87. Serrano J.A., Novoa-Montero D. Review on human mycoses in South America. Rev Soc Ven Microbiol 2001, 21(2):41-68. Available at:, Accessed January 6, 2010. http://www.scielo.org.ve/scielo.php%3Fscript%3Dsci_arttext%26pid%3DS1315-25562001000200015%26lng%3Dpt%26nrm%3Diso%26tlng%3Den.
88. Gugnani H.C., Muotoe Okafor F. African histoplasmosis: a review. Rev Iberoam Micol 1997, 14(4):155-159.
89. Randhawa H.S. Occurrence of histoplasmosis in Asia. Mycopathologia 1970, 41(1):75-89.
90. Nissapatorn V., Lee C.K., Rohela M., et al. Spectrum of opportunistic infections among HIV-infected patients in Malaysia. Southeast Asian J Trop Med Public Health 2004, 35(Suppl 2):26-32.
91. Poonwan N., Imai T., Mekha N., et al. Genetic analysis of Histoplasma capsulatum strains isolated from clinical specimens in Thailand by a PCR-based random amplified polymorphic DNA method. J Clin Microbiol 1998, 36(10):3073-3076.
92. Harahap M., Nasution M.A. Dermatomycoses in Indonesia. Int J Dermatol 1984, 23(4):273-274.
93. Hector R., Laniado-Laborin R. Coccidioidomycosis-a fungal disease of the Americas. PLoS Med 2005, 2(1):e2.
94. Gatti F., De Broe M., Ajello L. Blastomycosis dermatitidis infection of the Congo. Report of a second autochthonous case. Am J Trop Med Hyg 1968, 17:96-101.
95. Jerray M., Hayouni A., Benzarti M., et al. Blastomycosis in Africa: a new case from Tunisia. Eur Respir J 1992, 5:365-367.